Vertex Pharmaceuticals Incorporated which can be found using ticker (VRTX) now have 32 analysts in total covering the stock. The consensus rating is pointing to ‘buy’. The range between the high target price and low target price is between $602.00 and $325.00 and has a mean target at $513.87. Now with the previous closing price of $465.70 and the analysts are correct then we can expect a percentage increase in value of 10.3%. Also worth taking note is the 50 day moving average now sits at $476.31 and the 200 moving average now moves to $453.78. The total market capitalization for the company now stands at 120.27B. The current share price for the company is: $467.01 USD
The potential market cap would be $132,708,041,599 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of -, revenue per share of $41.19 and a 12.05% return on assets.
Vertex Pharmaceuticals Incorporated is a global biotechnology company. The Company is focused on developing medicines that treat the underlying cause of cystic fibrosis (CF). Its pipeline includes mid- and late-stage clinical programs in sickle cell disease, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, and alpha-1 antitrypsin deficiency, and earlier-stage programs in diseases such as muscular dystrophies. Its marketed medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor/ivacaftor and ivacaftor), ORKAMBI (lumacaftor/ivacaftor) and KALYDECO (ivacaftor). The Company has a pipeline of investigational small molecule, cell and genetic therapies in other serious diseases where it has deep insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, pain, type 1 diabetes, alpha-1 antitrypsin deficiency and Duchenne muscular dystrophy.
